- NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 5, 2025.
- CEO Mike Kelly will deliver the presentation, available via live webcast and subsequently archived on NervGen's website.
- The company is focusing on neurorestorative therapeutics and is currently in clinical trials for their lead candidate, NVG-291.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company specializing in neurorestorative therapeutics, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The conference will take place in Toronto, and NervGen's presentation is scheduled for Monday, May 5, 2025, at 10:00 a.m. EDT.
Mike Kelly, the President and CEO of NervGen, will present insights into the company's developmental strategies, particularly their focus on nervous system repair. Investors will have the opportunity to engage with the management team during one-on-one meetings throughout the conference.
For those unable to attend in person, a webcast of the presentation will be made available online. It will also be archived on NervGen's website for later viewing, ensuring accessibility for all interested parties.
NervGen is actively working on NVG-291, their pioneering therapeutic aimed at promoting repair in neurotrauma and neurologic disease settings. NVG-291 is currently undergoing Phase 1b/2a clinical trials for spinal cord injuries and has received Fast Track designation from the FDA.
